arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Jasper Therapeutics, Inc.

JSPR

$0.70 ▲ +0.05 (+8.44%) at close

7 Visible periods

19 Metrics

Absolute Benchmarks

Price Chart

Health

Fair

Bearish Absolute basis

auto_awesome

Analytical Summary

On an absolute basis, Jasper Therapeutics, Inc. shows weak fundamentals, weighed down by Return on Invested Capital. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $13.4M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -1596.4% ↘

FCF / Share $-4.03 ↗

Trailing P/E —

Price / Book 4.7x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-75.80M

↓ -6.4% —

FCF / Share Free cash flow per share

$-4.03

↑ +6.2% —

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Invested CapitalReturn on Invested Capital of -1596.4% is weak on an absolute basis (target > 10%)

Health Breakdown

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
EPS Growth YoY (%)	19.2% Good ↑ Good Improving Year-over-year change in earnings per share Optimal: > 10%	20.9% Good ↑ Good Improving Year-over-year change in earnings per share Optimal: > 10%	40.2% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	-284.0% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—
Net Income Growth YoY (%)	-6.4% Weak ↑ Weak Improving Year-over-year change in net income	-10.6% Weak ↑ Weak Improving Year-over-year change in net income	-71.1% Weak ↓ Weak Declining Year-over-year change in net income	-23.0% Weak Weak Year-over-year change in net income	3.3% Caution Caution Year-over-year change in net income	—	—
FCF Growth YoY (%)	6.2% Fair ↑ Fair Improving Year-over-year change in free cash flow	13.9% Fair ↑ Fair Improving Year-over-year change in free cash flow	60.3% Excellent Excellent Year-over-year change in free cash flow	-325.3% Weak Weak Year-over-year change in free cash flow	—	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
FCF / Net Income (x)	1.02x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.88x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.81x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.22x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	1.10x Fair Fair Free cash flow relative to reported net income Optimal: > 1x	0.58x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-1596.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-97.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-69.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-112.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-41.9% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	46.5% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-234.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-95.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-72.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-105.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-39.3% Weak Weak Operating profit relative to total assets Optimal: > 10%	-88.6% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	—	-115.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-870%)	-82.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-648%)	-104.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-798%)	-44.1% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-394%)	90.1% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+501%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Interest Coverage (x)	—	—	—	-445.18x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	-186.33x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-28.69M	$-71.64M	$-86.89M	$-38.25M	$-84.70M	$-19.84M	$-1.21M

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Basic EPS, GAAP (USD)	$-3.95	$-4.89	$-6.18	$-10.33	$-2.69	—	—
Free Cash Flow per Share (USD)	$-4.03	$-4.29	$-4.99	$-12.57	$-2.96	—	—
Book Value per Share (USD)	$0.15	$4.11	$7.03	$9.46	$1.84	$-12.68	—
Tangible Book Value per Share (USD)	$0.15	$4.11	$7.03	$9.46	$1.84	$-12.68	—
Basic Weighted Avg Shares (shares)	19.17M	14.58M	10.44M	3.65M	11.39M	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$21.45M	$60.57M	$76.56M	$34.67M	$79.81M	$16.67M	$1.43M
Total Equity (USD)	$4.15M	$61.67M	$78.44M	$35.99M	$69.52M	$-35.13M	$5.00M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Depreciation Expense (USD)	—	—	—	$975.00K	—	—	—
Net Income, GAAP (USD)	$-75.80M	$-71.27M	$-64.47M	$-37.69M	$-30.64M	$-31.67M	—
Operating Cash Flow (USD)	$-77.16M	$-62.60M	$-52.07M	$-45.86M	$-33.68M	$-18.27M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 28 quarters

Jasper Therapeutics, Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Benchmarks unavailable

Compare JSPR with peers